Evidence map›Paper›PMID 37490805›Full record

ArticleNuclear medicine and biology

Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer.

S L V Hoffman, J C Mixdorf, O Kwon, T R Johnson, M Makvandi, H Lee, E Aluicio-Sarduy, T E Barnhart, J J Jeffery, M S Patankar and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuclear medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.European journal of nuclear medicine and molecular imaging · 2026
    Review
  2. Article
  3. Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Advances in Radioligand Theranostics in Oncology.Molecular diagnosis & therapy · 2024
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

S L V HoffmanDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
J C MixdorfDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
O KwonDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
T R JohnsonDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
M MakvandiDepartment of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
H LeeDepartment of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
E Aluicio-SarduyDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
T E BarnhartDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
J J JefferyUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
M S PatankarDepartment of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
J W EngleDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
B P BednarzDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
P A EllisonDepartment of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. Electronic address: paellison@wisc.edu.
University of Wisconsin–Madison · USUniversity of Pennsylvania · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Radionuclide Production and Radiochemistry Core Description CoreP01CA250972 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEDNARZ, BRYAN PATRICK · 2020 to 2024
$12.5M
U.W. RADIOLOGICAL SCIENCES TRAINING PROGRAMT32CA009206 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Bryan Patrick Bednarz · 1985 to 2026
$12.1M
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0M
NCATS NIH HHS UL1 TR002373NCI NIH HHS P01 CA250972NCI NIH HHS P30 CA014520NCI NIH HHS T32 CA009206NCI NIH HHS U01 CA233102
6 · The paper itself

Abstract

Advanced ovarian cancer currently has few therapeutic options. Poly(ADP-ribose) polymerase (PARP) inhibitors bind to nuclear PARP and trap the protein-inhibitor complex to DNA. This work investigates a theranostic PARP inhibitor for targeted radiopharmaceutical therapy of ovarian cancer in vitro and PET imaging of healthy mice in vivo.

methods[

resultsThe maximum specific binding (B

conclusion[

Indexed as

Ovarian NeoplasmsRadiopharmaceuticalsAnimalsCell Line, TumorFemaleHumansMicePoly(ADP-ribose) Polymerase InhibitorsPositron Emission Tomography Computed TomographyPrecision MedicineTissue DistributionPoly(ADP-ribose) Polymerase InhibitorsRadiopharmaceuticalsBromine-76Bromine-77Meitner-Auger radionuclide therapyOvarian cancer therapyPARP-1 inhibitorPositron emission tomographyTheranostic

Identifiers

PMID37490805
PMCPMC10529069
OpenAlexW4384831513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.